Skip to main content

Table 3 Association between Age, HPV genotype and cervical Cancer

From: Human papillomavirus type-specific distribution in cervical intraepithelial neoplasia and cancer in The Gambia prior to HPV immunization programme: a baseline for monitoring the quadrivalent vaccine

Variable

Age in years

n (%)

Fisher’s exact test

P-value

 

21–31

32–42

43–53

54–64

65–75

76–86

  

Diagnosis (n = 338)

      

11.4

0.023*

Cervical Cancer

11 (3.3)

82 (24.3)

100 (29.6)

79 (23.4)

45 (13.3)

9 (2.7)

  

Not Cervical Cancer

1 (0.3)

4 (1.2)

3 (0.9)

3 (0.9)

-

-

  

HPV Result (n = 119)

      

2.4

0.790

Positive

3 (2.5)

30 (25.2)

29 (24.4)

24 (20.2)

15 (12.6)

3 (2.5)

  

Negative

-

3 (2.5)

6 (5.0)

3 (2.5)

2 (10.5)

1 (0.8)

  

HPV Genotype (n = 104)

        

HPV 16

1 (0.9)

15 (14.4)

19 (18.3)

10 (9.6)

11 (10.6)

-

16.04

0.041*

HPV18

1 (0.9)

7 (6.7)

2 (1.9)

4 (3.8)

2 (1.9)

-

4.8

0.564

HPV 16 /18

-

1 (0.9)

2 (1.9)

1 (0.9)

-

-

1.3

0.971

HPV 16 /other HR-HPV

-

-

4 (4.8)

2 (1.9)

1 (0.9)

1 (0.9)

6.41

0.379

HPV 18 / other HR-HPV

-

-

-

1 (0.9)

-

1 (0.9)

18.95

0.004*

Other HR-HPV

1 (0.9)

7 (6.7)

2 (1.9)

6 (5.8)

1 (0.9)

1 (0.9)

6.06

0.416